Objective: Antiepileptic drugs are often used in patients with some degree of renal
impairment. The objective of this study was to evaluate the effect of renal function on the …

Objective To evaluate the effect of moderate liver impairment on the pharmacokinetics of
eslicarbazepine acetate (BIA 2-093, ESL), a novel voltage-gated sodium channel blocker …

AES Proceedings Page 1 Epilepsia, 46(Suppl. 8):1–373, 2005 Blackwell Publishing, Inc. C o
International League Against Epilepsy AES Proceedings Annual Meeting of the American …

Eslicarbazepine acetate (ESL) is a novel once‐daily antiepileptic drug (AED) approved in
Europe since 2009 that was found to be efficacious and well tolerated in a phase III clinical …

OBJECTIVE: To evaluate the pharmacokinetics of eslicarbazepine acetate (ESL) at steady-
state in adults with partial-onset seizures who have taken ESL for at least 1 year with one or …

Abstract Background: Eslicarbazepine acetate (Zebenix®) is a voltage-gated sodium
channel blocker approved in 2009 by the European Medicines Agency as adjunctive …

Purpose: To evaluate the pharmacokinetics and tolerability of once‐daily eslicarbazepine
acetate (ESL) and twice‐daily oxcarbazepine (OXC) and their metabolites in cerebrospinal …

Background Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED), still
insufficiently studied regarding pharmacokinetic variability, efficacy and tolerability. The …

Eslicarbazepine acetate (ESL) is a new antiepileptic drug whose mechanism of action is
blockade of the voltage-gated sodium channel (VGSC). However, in respect to …

Purpose: To investigate the bioavailability and bioequivalence of three different formulations
of eslicarbazepine acetate (BIA 2-093): 50 mg/mL oral suspension (test 1), 200mg tablets …